News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,649 Results
Type
Article (13795)
Company Profile (101)
Press Release (251753)
Section
Business (88205)
Career Advice (467)
Deals (15367)
Drug Delivery (67)
Drug Development (36651)
Employer Resources (49)
FDA (6300)
Job Trends (6215)
News (150463)
Policy (14047)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (443)
Adcomms (6)
Allergies (32)
Alliances (23254)
ALS (36)
Alzheimer's disease (385)
Antibody-drug conjugate (ADC) (35)
Approvals (6338)
Artificial intelligence (101)
Autoimmune disease (7)
Automation (3)
Bankruptcy (150)
Best Places to Work (4385)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (18)
Brain cancer (15)
Breast cancer (75)
Cancer (574)
Cardiovascular disease (67)
Career advice (409)
Career pathing (11)
CAR-T (20)
Cell therapy (82)
Cervical cancer (4)
Clinical research (30895)
Collaboration (321)
Compensation (131)
Complete response letters (17)
COVID-19 (761)
CRISPR (19)
C-suite (112)
Cystic fibrosis (35)
Data (587)
Denatured (15)
Depression (9)
Diabetes (76)
Diagnostics (1318)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (64)
Drug shortages (13)
Duchenne muscular dystrophy (33)
Earnings (32085)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37459)
Executive appointments (346)
FDA (6688)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (203)
Gene editing (37)
Generative AI (8)
Gene therapy (98)
GLP-1 (336)
Government (1288)
Grass and pollen (2)
Guidances (15)
Healthcare (3582)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (33)
Indications (12)
Infectious disease (793)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (43)
Interviews (60)
IPO (5880)
IRA (29)
Job creations (2054)
Job search strategy (374)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3433)
Liver cancer (19)
Lung cancer (76)
Lymphoma (50)
Machine learning (1)
Management (16)
Manufacturing (141)
MASH (31)
Medical device (1294)
Medtech (1296)
Mergers & acquisitions (9674)
Metabolic disorders (245)
Multiple sclerosis (18)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (547)
NextGen: Class of 2025 (1602)
Non-profit (604)
Northern California (668)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (49)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (7)
Patents (102)
Patient recruitment (28)
Peanut (10)
People (28912)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8044)
Phase II (13077)
Phase III (11723)
Pipeline (381)
Podcasts (46)
Policy (58)
Postmarket research (1403)
Preclinical (3211)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (156)
Real estate (2641)
Recruiting (17)
Regulatory (10094)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (6)
Schizophrenia (33)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (680)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6761)
Vaccines (149)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (32)
Last 7 days (212)
Last 30 days (881)
Last 365 days (12089)
2025 (2897)
2024 (12515)
2023 (14273)
2022 (19585)
2021 (20110)
2020 (19085)
2019 (14964)
2018 (11765)
2017 (13919)
2016 (13175)
2015 (15497)
2014 (12453)
2013 (10608)
2012 (11414)
2011 (11941)
2010 (10905)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20103)
Australia (2603)
California (1615)
Canada (867)
China (226)
Colorado (65)
Connecticut (65)
Delaware (51)
Europe (39392)
Florida (299)
Georgia (35)
Idaho (9)
Illinois (181)
India (14)
Indiana (128)
Iowa (1)
Japan (85)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1386)
Michigan (29)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (7)
New Jersey (701)
New Mexico (7)
New York (468)
North Carolina (378)
North Dakota (2)
Northern California (668)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (408)
Puerto Rico (8)
Rhode Island (7)
South America (502)
South Carolina (2)
Southern California (680)
Tennessee (34)
Texas (217)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (110)
Wisconsin (14)
265,649 Results for "eagle pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Eagle Pharmaceuticals Announces Management Change
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a change in management.
November 29, 2023
·
5 min read
Pharm Country
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.
January 18, 2024
·
7 min read
Policy
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Eagle Pharmaceuticals, Inc. announced that it received a notice on May 20, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that it has initiated a process to delist the Company’s securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 and its Form 10-K for the year ended December 31, 2023 by May 13, 2024.
May 22, 2024
·
7 min read
Pharm Country
Eagle Pharmaceuticals Granted Patent for PEMFEXY®
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food and Drug Administration’s Orange Book.
October 24, 2023
·
5 min read
Pharm Country
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride
Eagle Pharmaceuticals, Inc. today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024.
April 30, 2024
·
9 min read
Press Releases
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
November 18, 2024
·
7 min read
Pharm Country
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference 2023.
September 19, 2023
·
1 min read
Policy
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
Eagle Pharmaceuticals, Inc. announced that it received a notice on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
April 12, 2024
·
7 min read
Business
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
Eagle Pharmaceuticals, Inc. today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens.
November 8, 2023
·
1 min read
Pharm Country
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code and granted transitional pass-through payment status for Barhemsys (amisulpride) injection.
October 23, 2023
·
10 min read
1 of 26,565
Next